Abstract: A topical preparation containing vitamin K1 and a preparation method thereof are provided. The topical preparation includes the following components in weight percentage: 0.01-5% of vitamin K1, 0.1-25% of a transdermal enhancer and 70-99% of a matrix for the topical preparation. The transdermal enhancer is composed of urea, menthol and Eucalyptus oil in a mass ratio of (5-6):(2-3):(1-3). The topical preparation containing vitamin K1 can be used to treat moderate and severe skin toxicity caused by anti-tumor drugs related to epidermal growth factor receptor (EGFR), can effectively treat diseases such as acne-like rash, pruritus, red swelling, dry skin and mucositis caused by EGFR-related anti-tumor drugs, and can ensure the continued treatment with anti-EGFR targeting drugs. It can increase the possibility of vitamin K1 reaching focus sites in the dermal layer through the stratum corneum, and can rapidly alleviate moderate and severe skin diseases caused by EGFR-related anti-tumor drugs.

Abstract: A topical preparation containing vitamin K1 and a preparation method thereof are provided. The topical preparation includes the following components in weight percentage: 0.01-5% of vitamin K1, 0.1-25% of a transdermal enhancer and 70-99% of a matrix for the topical preparation. The transdermal enhancer is composed of urea, menthol and eucalyptus oil in a mass ratio of (5-6):(2-3):(1-3). The topical preparation containing vitamin K1 can be used to treat moderate and severe skin toxicity caused by anti-tumor drugs related to epidermal growth factor receptor (EGFR), can effectively treat diseases such as acne-like rash, pruritus, red swelling, dry skin and mucositis caused by EGFR-related anti-tumor drugs, and can ensure the continued treatment with anti-EGFR targeting drugs. It can increase the possibility of vitamin K1 reaching focus sites in the dermal layer through the stratum corneum, and can rapidly alleviate moderate and severe skin diseases caused by EGFR-related anti-tumor drugs.